Aeglea BioTherapeutics, Inc. (AGLE) Comparison with companies in other sectors?

Aeglea BioTherapeutics, Inc. has a share price of 4.05M. You can analyze Aeglea BioTherapeutics, Inc. (AGLE) competitors across different market sectors through stock heatmaps.

What are AGLE's NET and operating margins?

Aeglea BioTherapeutics, Inc. (AGLE) operating margin is around 186.55, and net profit margin is approximately 95.99 as of the latest reports.

In what way does AGLE's earnings per share (EPS) trend reflect its financial momentum?

Aeglea BioTherapeutics, Inc. (AGLE) EPS is -74.15 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Aeglea BioTherapeutics, Inc. is -0.16, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Aeglea BioTherapeutics, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Aeglea BioTherapeutics, Inc. like P/E which is -48.87, P/B which is 8.61, and PEG which is -0.63. Compare them with sector averages to evaluate if the stock is priced fairly.

Aeglea BioTherapeutics, Inc.

AGLE•NASDAQ

Healthcare

Biotechnology

$12.01

$0.75(6.66%)

Fundamental Analysis of Aeglea BioTherapeutics, Inc. (AGLE)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-74.15

P/E Ratio

-0.16

ROE

-0.20%

Net Margin

95.99%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$48.63M

Shares OutstandingTotal number of shares issued

$4.05M

Book Value/ShareNet worth per share

$1.39

Revenue/ShareAnnual revenue per share

$-0.00

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-74.15

Net MarginNet income as percentage of revenue

9598.87%

Operating MarginOperating income as percentage of revenue

18654.97%

ROEReturn on shareholders' equity

-19.99%

ROAReturn on total assets

-14.93%

ROCEReturn on capital employed

-33.12%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.64

Cash/ShareCash and equivalents per share

$1.63

FCF YieldFree cash flow as percentage of market cap

-454.88%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for AGLEFinancial Ratios Analysis details for AGLE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for AGLESector Benchmarking details for AGLE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Aeglea BioTherapeutics, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Aeglea BioTherapeutics, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Aeglea BioTherapeutics, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Aeglea BioTherapeutics, Inc.

For Aeglea BioTherapeutics, Inc., essential financial indicators include EPS -74.15, PE -0.16, and ROE -0.20. These key ratios reveal insights into Aeglea BioTherapeutics, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Aeglea BioTherapeutics, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Aeglea BioTherapeutics, Inc.

Metrics like Net Margin 9598.87% and ROA -14.93% shed light on how well Aeglea BioTherapeutics, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Aeglea BioTherapeutics, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Aeglea BioTherapeutics, Inc.

Using ratios such as P/B Ratio 8.61 and PEG Ratio -0.63, investors can assess whether Aeglea BioTherapeutics, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Aeglea BioTherapeutics, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Aeglea BioTherapeutics, Inc.

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow $-0.64, provide a snapshot of Aeglea BioTherapeutics, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Aeglea BioTherapeutics, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Aeglea BioTherapeutics, Inc.

Investing in Aeglea BioTherapeutics, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Aeglea BioTherapeutics, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;